UK markets closed
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • FTSE 250

    22,324.19
    -210.95 (-0.94%)
     
  • AIM

    1,229.80
    -11.57 (-0.93%)
     
  • GBP/EUR

    1.1636
    -0.0053 (-0.46%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • BTC-GBP

    25,817.06
    -1,380.19 (-5.07%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • DOW

    33,290.08
    -533.37 (-1.58%)
     
  • CRUDE OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD FUTURES

    1,763.90
    -10.90 (-0.61%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     
  • HANG SENG

    28,801.27
    +242.68 (+0.85%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • CAC 40

    6,569.16
    -97.10 (-1.46%)
     

Guillain-Barre Syndrome Therapeutics Market Report 2021 - Global Trajectory & Analytics, 2012-2019 & 2020-2027 - ResearchAndMarkets.com

·3-min read

The "Guillain-Barre Syndrome Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Guillain-Barre Syndrome Therapeutics Market to Reach $679.6 Million by 2027

Amid the COVID-19 crisis, the global market for Guillain-Barre Syndrome Therapeutics estimated at US$491.1 Million in the year 2020, is projected to reach a revised size of US$679.6 Million by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027.

Intravenous Immunoglobulin, one of the segments analyzed in the report, is projected to record a 5% CAGR and reach US$383.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Plasma Exchange segment is readjusted to a revised 4.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $144.7 Million, While China is Forecast to Grow at 4.5% CAGR

The Guillain-Barre Syndrome Therapeutics market in the U.S. is estimated at US$144.7 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$120.4 Million by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Other Therapeutics Segment to Record 3.9% CAGR

In the global Other Therapeutics segment, USA, Canada, Japan, China and Europe will drive the 4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$56 Million in the year 2020 will reach a projected size of US$73.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$75.8 Million by the year 2027.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 42 Featured):

  • Akari Therapeutics Plc

  • Biotest AG

  • China Biologic Products Holdings, Inc.

  • CSL Behring LLC

  • Grifols SA

  • Kedrion SpA

  • Nihon Pharmaceutical Co., Ltd.

  • Octapharma AG

  • Shire PLC

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

  • World 15-Year Perspective for Intravenous Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Plasma Exchange by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 42

For more information about this report visit https://www.researchandmarkets.com/r/k0lbs3

View source version on businesswire.com: https://www.businesswire.com/news/home/20210507005248/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting